Related Experiment Videos

Relationship between CD40 ligand expression and B type natriuretic peptide levels in patients with chronic heart

Jin-Chuan Yan1, Pei-Jing Liu, Rong-Zeng Du

  • 1Department of Cardiology, Affiliated Hospital of JiangSu University, Zhenjiang 212001, China. yanjinchuan@hotmail.com

Clinica Chimica Acta; International Journal of Clinical Chemistry
|March 15, 2008
PubMed

Insights

Chronic heart failure (CHF) patients exhibit elevated CD40 ligand (CD40L) expression on platelets and in soluble form. This increased CD40L may contribute to the development and worsening of CHF, highlighting a potential therapeutic target.

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Inflammation is a key factor in chronic heart failure (CHF) pathogenesis.
  • CD40-CD40 ligand (CD40L) interactions are implicated in inflammatory disorders.
  • The role of CD40L in CHF requires further investigation.

Purpose of the Study:

  • To evaluate CD40L expression in patients with CHF.
  • To determine if CD40L levels correlate with CHF severity.
  • To explore the pathogenic role of CD40L in CHF.

Main Methods:

  • Compared CD40L expression on platelets and soluble CD40L (sCD40L) levels in 86 CHF patients and 20 controls.
  • Utilized indirect-immunofluorescence flow cytometry for platelet CD40L analysis.
  • Employed ELISA for sCD40L and radioimmunoassay for B-type natriuretic peptide (BNP).

Main Results:

  • CHF patients demonstrated significantly higher platelet CD40L expression and sCD40L levels versus controls (p<0.0001).
  • Elevated CD40L and sCD40L levels correlated positively with NYHA functional class, left ventricular ejection fraction, and BNP levels.
  • These findings suggest a link between CD40L system activity and CHF severity.

Conclusions:

  • Patients with CHF exhibit increased CD40L system expression.
  • This heightened CD40L activity may play a pathogenic role in CHF development and progression.
  • Targeting the CD40L pathway could be a potential therapeutic strategy for CHF.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...